Genzyme,
a Sanofi company SNY, announced today that the
Food and Drug Administration (FDA) has granted a six-month Priority
Review designation to its New Drug Application (NDA) for Cerdelga™
(eliglustat), an investigational oral therapy for adult patients with
Gaucher disease type 1. As previously announced, the European Medicines
Agency in late October validated Genzyme's marketing authorization
application (MAA) for eliglustat in the EU.
Genzyme is developing eliglustat, a capsule to be taken twice daily, to
provide an effective oral treatment alternative for adult patients with
Gaucher disease type 1, and to provide a broader range of treatment
options for Gaucher patients and physicians. Genzyme's clinical
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in